Navigation Links
New Study Shows Viability of Heart Pumps for Older Heart-Failure Patients

SAN DIEGO, June 28, 2011 /PRNewswire/ -- Results of a clinical research study at Sharp Memorial Hospital indicate that patients 70 years of age or older have good functional recovery, survival and quality of life at two years when undergoing left ventricular assist device (LVAD) therapy for heart failure.  The study was released in the June 21 edition of the Journal of the American College of Cardiology.


The study's lead author, Robert M. Adamson, MD, medical director of the cardiac transplantation program at Sharp Memorial, and colleagues concluded that LVAD therapy should be considered an "attractive option" for some patients, and that advanced age alone should not determine whether or not a patient receives LVAD support.  The research team also noted that "very good results can be achieved in a community hospital setting with a focused effort from a dedicated team."

Patients in the study were implanted with Thoratec's HeartMate II LVAD, which received FDA approval for bridge to transplantation therapy in April 2008 and for destination therapy in January 2010 for transplant-ineligible heart-failure patients.  At Sharp Memorial, which serves as a Thoratec training site, the transplant team has implanted nearly 130 HeartMate II devices.  The physicians and staff there have been working together since the 1980s and performed San Diego's first heart transplant in 1985.  Since then, the team has performed more than 340 heart transplants and numerous implant procedures.  They also have the longest LVAD-supported patient in the world, who first received the device more than nine years ago in March 2002.  

"With an increasing population of elderly patients with advanced heart failure who have limited treatment options, the FDA's approval of LVAD therapy make sense for many individuals," said Dr. Adamson.  "Older patients in the study were very appreciative of the improved quality of life afforded by LVAD therapy.  While younger patients want to live longer, older patients want to live better."

During the research period, 55 patients received the HeartMate II between Oct. 5, 2005, and Jan. 1, 2010, as part of either bridge to transplantation or destination therapy trials. Patients were separated into two age groups: 70 years of age or younger (30 patients) and older than 70 years of age (25 patients). Pre-operatively, all patients were classified as having severe heart failure, showing symptoms of cardiac insufficiency at rest (New York Heart Association Class IV). The research team compared outcome measures between the two groups including survival, length of hospital stay, adverse events and quality of life.

The survival rate between the two groups was not statistically different.  For patients older than 70, the survival rate was 97 percent at one month, 75 percent at one year and 70 percent at two years.  For patients 70 and younger, the rate was 96 percent at one month, 72 percent at one year and 65 percent at two years.  

The average length of hospital stay for the older group was 24 days, which was similar to length of stay for the younger group (23 days). The researchers found no differences in the incidence of adverse events between the two groups, and quality of life and functional status improved significantly in both groups.

Co-authors of the study at Sharp Memorial include Marcia Stahovich, RN; Suzanne Chillcott, BSN; Sam Baradarian, MD; Joseph Chammas, MD; Brian Jaski, MD; Peter Hoagland, MD and Walter Dembitsky, MD.

About Sharp Memorial Hospital

Sharp Memorial Hospital, which first opened its doors in 1955, is part of Sharp HealthCare, San Diego's most comprehensive health care delivery system, recognized for clinical excellence in cardiac care, women's services, cancer, orthopedics, multi-organ transplants, rehabilitation and behavioral health services. To learn more about Sharp Memorial, visit or call 1-800-82-SHARP (1-800-827-4277).

SOURCE Sharp HealthCare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
(Date:11/26/2015)... -- Research and Markets ( ) has announced ... by Type (Dressings, Therapy Devices, Active Wound Care), Application ... and Geography - Global Forecast to 2020" report ... --> The purpose of this report is ... global advanced wound care market. It involves deep dive ...
(Date:11/26/2015)... , November 26, 2015 ... --> adds "Global Repaglinide ... "Investigation Report on China Repaglinide Market, ... forecasts data and information to its ... . --> ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... , ... Key Housing, a top-rated corporate housing service for the San Jose ... Epic. In showcasing this featured apartment community in San Jose, Key Housing is helping ... efficiently find housing suitable to their needs by showcasing quality housing. , “San Jose ...
(Date:11/28/2015)... ... November 28, 2015 , ... Trying to relax on a ... COUCH BUDDY. "I conceived of this design due to personal experience with a bad ... It promotes relaxation and convenience, as well as increases support. It also makes it ...
(Date:11/27/2015)... ... ... There is only one major question facing all law firms in the ... has not been an easy question to answer. Especially when the senior partners and ... don’t share the same discipline around working long hours. , In addition to ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... a safe and convenient way to dispense prescription medications at home, so he ... effective way to monitor and dispense prescription medications. In doing so, it could ...
Breaking Medicine News(10 mins):